BELLSHILL, SCOTLAND, 12 February 2013: Link Technologies Ltd, an ISO 9001:2008 certified specialist oligonucleotide reagent manufacturer, has undertaken a strategic review to ensure that customers receive top-quality products at the most competitive prices. Accordingly the company has reduced prices across a range of core, frequently-ordered products. By reducing the product list prices, and introducing standard quantity discounts, the purchase of oligo precursor products from Link Technologies is now a much clearer and more affordable option for all researchers.
The price reductions apply with immediate effect and have been made to a key collection of over 10 products which have been specifically identified as those that are most in demand, appearing on customer quote requests most frequently. They include amino and thiol linkers, biotin and 6-FAM labels, and PNA monomers among others.
Dr John Bremner, CEO at Link Technologies, explained: “Quality will always come first for our customers and remains our priority. However, we are challenging the perception that this only comes at a high cost. As a primary manufacturer of many of the most common products used in the industry we are ideally positioned to provide both high quality and highly competitive prices.”
Link Technologies provides a broad range of reagents for DNA, RNA and PNA synthesis and this step is the first of several upcoming developments to further benefit customers involved in oligo synthesis.
For further detail on the recent price changes, please click here, or for more information on the products offered by Link Technologies, please visit the website at www.linktech.co.uk or follow us on Twitter: @linktechdna.
About Link Technologies Ltd
Link Technologies Ltd is a leading kilo-scale supplier of speciality reagents for oligonucleotide synthesis and modification, all to the ISO 9001:2008 quality certification. The company’s main markets are university and commercial research departments, plus, increasingly, larger Contract Manufacturing Organisations (CMOs) in the biotech sector.
Link has also forged successful links to academia working closely with many UK universities. In tandem with internal research and development, the Company has an excellent record in bringing in-licence products to market with various worldwide commercial partners.
For further information see: www.linktech.co.uk.